Deacetylanisomycin is a derivative of the protein and DNA synthesis inhibitor anisomycin with antimalarial and anticancer activity.1,2 It inhibits the growth of the P. falciparum strains K1 and T9-96 in vitro (IC50s = 40.29 and 33.57 μM, respectively).1 Deacetylanisomycin is cytotoxic to LU99 lung carcinoma and MCF-7 breast cancer cells (IC50s = 23 and 34 μM, respectively). It has been used as a negative control for assessment of protein synthesis inhibitor activity in molluscan neurons.3
1.Ekong, R.M., Kirby, G.C., Patel, G., et al.Comparison of the in vitro activities of quassinoids with activity against Plasmodium falciparum, anisomycin and some other inhibitors of eukaryotic protein synthesisBiochem. Pharmacol.40(2)297-301(1990) 2.Hosoya, Y., Kameyama, T., Naganawa, H., et al.Anisomycin and new congeners active against human tumor cell linesJ. Antibiot. (Tokyo)46(8)1300-1302(1993) 3.Alkon, D.L., Bank, B., Naito, S., et al.Inhibition of protein synthesis prolongs Ca2+-mediated reduction of K+ currents in molluscan neuronsProc. Natl. Acad. Sci. USA84(19)6948-6952(1987)